FTC Says Three Is Not Enough: Lupin Must Divest To Acquire Gavis, Novel
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger would leave three companies selling antibiotic doxycycline, but Gavis must still transfer its product to G&W Laboratories as a condition of $850m acquisition.